Targeted Strategies for Today's Evolving Markets

MissionIR Blog

RXi Pharmaceuticals Corp. (RXII) Starts Presentation at 25th Annual ROTH Conference

Posted on March 19, 2013 by Mission IR

RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXII’s first RNAi product candidate, RXI-109, which targets CTGF, entered into human clinical development in June 2012. For more information, visit the company’s Web site: http://www.rxipharma.com

Let us hear your thoughts below:

This year's annual ROTH Conference will take place at The Ritz Carlton located in Laguna Niguel, on March 17-12, 2013. Bringing together executives from more than 400 growth companies, the ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com.
This entry was posted in ROTH Capital Partners Conference. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *